TOG Review (RCOG Journal)
MRCOG Part 2
Sexual and Reproductive Health
Female sexual dysfunction
Key Statistics
- 30–60% — Prevalence of sexual problems in women
- 21% — Women with problems who seek help
- 98% — Sexual concerns in gynae clinic attenders
Don't-miss facts
-
FSD criteria: present >75% of time, >6 months, causing significant distress
-
DSM-5: desire+arousal merged → sexual desire/arousal disorder; dyspareunia+vaginismus merged → genito-pelvic pain/penetration disorder
-
Only 21% of affected women seek help despite 30–60% prevalence – ask the screening question routinely
-
Basson's circular model: orgasm not essential for fulfilment; intimacy/emotional connection drives the cycle
-
Oophorectomy <50 years → consider HRT (± testosterone) for abrupt hormone loss
-
Testosterone trial: 3–6 months, check level at baseline + 3–6 weeks, then 6-monthly if continued
-
Failure to warn about post-surgical sexual dysfunction risk (e.g. vulvectomy, oophorectomy) is a recognised litigation risk
-
No surgery is designed to treat FSD – discuss realistic sexual-function expectations before any gynae operation
Evidence at a glance
Supported: pelvic floor physio, vaginal dilators + topical estrogen, topical/vaginal estrogen, testosterone (low desire), ospemifene (SERM)
Not licensed/insufficient evidence: sildenafil (FSD), flibanserin (UK), genital cosmetic surgery, hypnosis/TENS-type modalities
Abbreviation Key
- FSD — female sexual dysfunction
- SUI — stress urinary incontinence
- DSM — Diagnostic and Statistical Manual of Mental Disorders
- POP — pelvic organ prolapse
- ICD-10 — International Statistical Classification of Diseases and
- RCT — randomised controlled trial Related Health Problems
- HRT — hormone replacement therapy
- ICSM — International Consultation of Sexual Medicine
- FGM — female genital mutilation
- IUGA — International Urogynecological Association
- PTSD — post-traumatic stress disorder
- ICS — International Continence Society
- CBT — cognitive behavioural therapy
- NATSAL — National Surveys of Sexual Attitudes and Lifestyles
- IPM — Institute of Psychosexual Medicine
- GP — general practitioner
- SERM — selective estrogen receptor modulator (ospemifene)
- LOFTI — listening, observing, feelings, thinking and interpreting
- SSRI — selective serotonin reuptake inhibitor
- FSFI — Female Sexual Function Index
- cGMP — cyclic guanosine monophosphate
- PISQ-31 / PISQ-IR — Prolapse and Incontinence Sexual Function
- VIP — vasoactive intestinal peptide Questionnaire / IUGA-Revised
- FDA — US Food and Drug Administration
- GSM — genitourinary syndrome of menopause
- NICE — National Institute for Health and Care Excellence
- FSH — follicle-stimulating hormone
- ACOG — American College of Obstetrics and Gynecology
Source: Kershaw V, Jha S. Female sexual dysfunction. The Obstetrician & Gynaecologist 2022;24:12–23. doi:10.1111/tog.12778
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).